1114 GMT - Evonik posted a robust and solid set of numbers that came in line with expectations, Morgan Stanley analysts say in a research note. The German specialty-chemicals company saw both adjusted Ebitda and free-cash-flow figures ahead of Visible Alpha estimates. The company also backed its guidance for 2025 adjusted Ebitda in a range between 2.0 billion and 2.3 billion euros. "We judge that second-quarter Visible Alpha consensus [for adjusted Ebitda] at 574 million euros is likely secure given the trends in methionine but note this looks low vs normal seasonality," they say. Shares trade 1.39% higher at 20.08 euros. (nina.kienle@wsj.com)
(END) Dow Jones Newswires
May 12, 2025 07:14 ET (11:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。